Bildkälla: Stockfoto

Medivir Q1 2023: Quick Recruitment in Phase IIa - Redeye

Redeye comments on Medivir’s first quarter report of 2023. During the quarter, the phase IIa part in which fostrox is combined with Lenvima was initiated. Recruitment is going ahead at a fast pace.

Redeye comments on Medivir’s first quarter report of 2023. During the quarter, the phase IIa part in which fostrox is combined with Lenvima was initiated. Recruitment is going ahead at a fast pace.
Börsvärldens nyhetsbrev
ANNONSER